New hope for fighting recurrent brain tumors with immune therapy

NCT ID NCT06069726

Recruiting now Disease control Sponsor: Duke University Source: ClinicalTrials.gov ↗

Summary

This study is testing if a drug called atezolizumab, given before surgery, can help control recurrent glioblastoma, a very aggressive brain cancer. It will enroll 80 adults whose cancer has returned after standard treatment and who have a specific tumor characteristic called low mutational burden. The main goal is to see if this immunotherapy approach improves survival compared to past treatments.

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••
Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

Duke University
RECRUITING

Durham, North Carolina, 27705, United States

Contact Phone: •••-•••-•••• Email: •••••@•••••

Contact Phone: •••-•••-•••• Email: •••••@•••••

Contact
Huntsman Cancer Institute
RECRUITING

Salt Lake City, Utah, 84112, United States

Contact Phone: •••-•••-•••• Email: •••••@•••••

Contact Phone: •••-•••-•••• Email: •••••@•••••
Saint Luke's Cancer Institute
RECRUITING

Kansas City, Missouri, 64111, United States

Contact Phone: •••-•••-•••• Email: •••••@•••••

Contact Phone: •••-•••-•••• Email: •••••@•••••
University of California, San Francisco
RECRUITING

San Francisco, California, 94143, United States

Contact Phone: •••-•••-•••• Email: •••••@•••••

Conditions

Explore the condition pages connected to this study.

RECURRENT GLIOBLASTOMA